natgillin/translations-raw huggingface dataset:
Voriconazole has been shown to be more selective for fungal cytochrome P450 enzymes than for various mammalian cytochrome P-450 enzyme systems.
Vorikonazol je pokazao veću selektivnost za enzime gljivičnog citokroma P450 nego za različite enzimske sustave citokroma P450 u sisavaca.
Methadone (32-100 mg QD)
Metadon (32-100 mg QD)
Dose reduction of sulfonylureas should be considered
Treba razmotriti smanjenje doze sulfonilureje.
In the table below, since the majority of the studies were of an open nature, all causality adverse reactions and their frequency categories in 1,873 adults from pooled therapeutic (1,603) and prophylaxis (270) studies, by system organ class, are listed.
S obzirom da je većina ispitivanja bila otvorenog tipa, u sljedećoj su tablici navedene nuspojave svih uzroka i i kategorije učestalosti kod 1873 odrasle osobe iz kombiniranih terapeutskih (1603) i profilaktičkih (270) ispitivanja, razvrstane prema organskim sustavima.
Considering the assumed limited gastro-enteric transit time in paediatric patients, the absorption of tablets may be different in paediatric compared to adult patients.
S obzirom na pretpostavljeno kratko vrijeme prolaska kroz probavni sustav u pedijatrijskih bolesnika, moguća je i razlika u apsorpciji tableta između pedijatrijskih i odraslih bolesnika.
Very common: may affect more than 1 in 10 people
Vrlo česte nuspojave: mogu se javiti u više od 1 na 10 osoba
If you are already being treated with rifabutin your blood counts and side effects to rifabutin will need to be monitored.
Ako već primate rifabutin, morat će se kontrolirati krvna slika i pratiti moguća pojava nuspojave na rifabutin.
In a secondary analysis, which utilised DRC assessments at the latest evaluable time point (EOT, or 2, 6, or 12 weeks after EOT) voriconazole and the regimen of amphotericin B followed by fluconazole had successful response rates of 65% and 71%, respectively.
U sekundarnoj analizi u kojoj su korištene ocjene DRC-a u posljednjoj dostupnoj vremenskoj točki (završetak liječenja, odnosno 2, 6 ili 12 tjedana po završetku liječenja), udio pozitivnog odgovora u skupini liječenoj vorikonazolom iznosio je 65%, a u skupini liječenoj amfotericinom B pa potom flukonazolom 71%.
Tell your doctor if you are taking the following medicine, as treatment with Voriconazole Accord at the same time should be avoided if possible:
Obavijestite svog liječnika ako uzimate sljedeći lijek, jer treba izbjegavati istodobno liječenje lijekom Voriconazole Accord ako je to moguće:
cutaneous lupus erythemato sus*, ephelides*, lentigo*
kožni lupus eritematodes *, pjege*, lentigo*
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Blister (Blister foil for 200 mg film-coated tablets (all blister packs))
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP Blister (Blister folija za 200 mg filmom obložene tablete (sva blister pakiranja))
Although not studied, increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences of torsades de pointes
Iako nije ispitivano, povišene koncentracije ovih lijekova u plazmi mogu dovesti do produljenja QTc-intervala, a u rijetkim slučajevima i do torsades de pointes.
EU/1/13/835/025-030
EU/1/13/835/010-018, EU/1/13/835/025-030
After IV voriconazole therapy, the median duration of oral voriconazole therapy was 76 days (range 2232days).
Nakon intravenskog je liječenja medijan trajanja peroralne primjene vorikonazola iznosio 76 dana (raspon 2-232 dana).
Voriconazole should be administered with caution in patients with concomitant medication that is known to prolong QTc interval.
Vorikonazol treba primjenjivati s oprezom u bolesnika koji istodobno primaju lijek koji produljuju QTc-interval.
Visual impairments may be associated with higher plasma concentrations and/or doses.
Moguće je da su povezani s višim koncentracijama lijeka u plazmi i/ili višim dozama.
Voriconazole should be dosed as adults.
Vorikonazol se treba dozirati kao kod odraslih.
Ciclosporin Cmax  13% Ciclosporin AUCτ  70%
Ciklosporin Cmax  13% Ciklosporin AUC  70%
Contains lactose monohydrate.
Lijek sadrži laktozu hidrat.
If phototoxic reactions occur multidisciplinary advice should be sought, Voriconazole Accord discontinuation and use of alternative antifungal agents should be considered and the patient should be referred to a dermatologist.
Ako se pojavi fototoksična reakcija, treba zatražiti savjet multidisciplinarnog tima, razmotriti prekid primjene lijeka Voriconazole Accord i primjenu zamjenskih antimikotika te bolesnika uputiti dermatologu.
Treatment of candidaemia in non-neutropenic patients.
Liječenje kandidemije u bolesnika koji nemaju neutropeniju.
There have been reports of skin cancer in patients treated with Voriconazole Accord for long periods of time.
Prijavljen je rak kože u bolesnika koji su liječeni lijekom Voriconazole Accord kroz duži vremenski period.
Long term exposure (treatment or prophylaxis) greater than 180 days (6 months) requires careful assessment of the benefit-risk balance and physicians should therefore consider the need to limit the exposure to Voriconazole Accord (see sections 4.2 and 5.1).
Dugotrajno izlaganje (liječenje ili profilaksa) duže od 180 dana (6 mjeseci) zahtijeva temeljitu procjenu omjera koristi i rizika pa stoga liječnici trebaju razmotriti treba li ograničiti izloženost lijeku Voriconazole Accord (vidjeti dijelove 4.2 i 5.1).
Breast-feeding must be stopped on initiation of treatment with Voriconazole Accord.
Dojenje se mora prekinuti prije početka liječenja lijekom Voriconazole Accord.
EU/1/13/835/010 2 film-coated tablets EU/1/13/835/011 10 film-coated tablets EU/1/13/835/012 14 film-coated tablets EU/1/13/835/013 20 film-coated tablets EU/1/13/835/014 28 film-coated tablets EU/1/13/835/015 30 film-coated tablets EU/1/13/835/016 50 film-coated tablets EU/1/13/835/017 56 film-coated tablets EU/1/13/835/018 100 film-coated tablets EU/1/13/835/025 10x1 film-coated tablets EU/1/13/835/026 14x1 film-coated tablets EU/1/13/835/027 28x1 film-coated tablets EU/1/13/835/028 30x1 film-coated tablets EU/1/13/835/029 56x1 film-coated tablets EU/1/13/835/030 100x1 film-coated tablets
EU/1/13/835/0102 filmom obložene tablete EU/1/13/835/011 10 filmom obloženih tableta EU/1/13/835/012 14 filmom obloženih tableta EU/1/13/835/013 20 filmom obloženih tableta EU/1/13/835/014 28 filmom obloženih tableta EU/1/13/835/015 30 filmom obloženih tableta EU/1/13/835/016 50 filmom obloženih tableta EU/1/13/835/017 56 filmom obloženih tableta EU/1/13/835/018 100 filmom obloženih tableta EU/1/13/835/025 10x1 filmom obložena tableta EU/1/13/835/026 14x1 filmom obložena tableta EU/1/13/835/027 28x1 filmom obložena tableta EU/1/13/835/028 30x1 filmom obložena tableta EU/1/13/835/029 56x1 filmom obložena tableta EU/1/13/835/030 100x1 filmom obložena tableta
Voriconazole Accord 50 mg film-coated tablets and 200mg film-coated tablets are available as packs of 2, 10, 14, 20, 28, 30, 50, 56 and 100 or unit dose blister packs (PVC / Aluminium) containing 10x1, 14x1, 28x1, 30x1, 56x1 or 100x1 film-coated tablets.
Voriconazole Accord 50 mg filmom obložene tablete i Voriconazole Accord 200 mg filmom obložene tablete dostupne su u pakiranjima od 2, 10, 14, 20, 28, 30, 50, 56 i 100 tableta ili blisteri (PVC/aluminij) s jediničnim dozama, u kutijama sa 10x1, 14x1, 28x1, 30x1, 56x1 ili 100x1 filmom obloženom tabletom.
Tell your doctor if you are taking either of the following medicines, as treatment with Voriconazole Accord at the same time should be avoided if possible, and a dose adjustment of voriconazole may be required:
Obavijestite svog liječnika ako uzimate bilo koji od sljedećih lijekova jer treba izbjegavati istodobno liječenje lijekom Voriconazole Accord, a možda će biti potrebno i prilagoditi dozu vorikonazola:
Endocrine disorders adrenal insufficiency, hypothyroidism hyperthyroidis m
Endokrini poremećaji insuficijencija nadbubrežnih žlijezda, hipotireoidizam hipertireoidiza m
• Sulfonylureas (e.g., tolbutamide, glipizide, and glyburide) (used for diabetes)
• sulfonilureje (tj. tolbutamid, glipizid, i gliburid) (koriste se za liječenje šećerne bolesti)
In an oral multiple-dose study Cmax and AUCτ in healthy elderly males (≥65 years) were 61% and 86 % higher, respectively, than in healthy young males (18-45 years).
U jednom ispitivanju s višekratnom primjenom peroralne doze lijeka Cmax je u zdravih starijih muškaraca bio je 61% veći, a AUCτ 86% veći nego u zdravih mladih muškaraca (18-45 godina).
Use of standard doses of voriconazole with efavirenz doses of 400 mg QD or higher is contraindicated (see section 4.3).
Primjena standardnih doza vorikonazola s dozama efavirenza od 400 mg QD ili većim je kontraindicirana (vidjeti dio 4.3).
Sirolimus Cmax  6.6-fold Sirolimus AUC0-∞ 11-fold
Sirolimus Cmax  6,6 puta Sirolimus AUC0- 11 puta
Vinca Alkaloids (e.g., vincristine and vinblastine)
Vinka alkaloidi (npr. vinkristin i vinblastin)
• tell your doctor immediately if you develop o sunburn o severe skin rash or blisters.
• odmah recite svom liječniku ako dobijete o opekline od sunca o teški osip ili mjehuriće po koži o bolove u kostima
• Oral contraceptives (if you take Voriconazole Accord whilst using oral contraceptives, you may get side effects such as nausea and menstrual disorders)
• oralne kontraceptive (ako uzimate Voriconazole Accord istodobno s oralnim kontraceptivima,
If you are already being treated with phenytoin your blood concentration of phenytoin will need to be monitored during your treatment with Voriconazole Accord and your dose may be adjusted.
Ako već primate fenitoin, za vrijeme liječenja lijekom Voriconazole Accord morat će se pratiti koncentracija fenitoina u krvi i možda prilagoditi doza lijeka.
Fentanyl (5 µg/kg single dose)
Fentanil (jedna doza od 5 g/kg)
In fluconazole-resistant non albicans species, a successful outcome was seen in3/3 C.krusei (complete responses) and 6/8 C. glabrata (5 complete, 1 partial response) infections.
Kod infekcija uzrokovanih drugim vrstama kandide osim C. albicans rezistentnima na flukonazol, pozitivan je odgovor zabilježen u 3/3 slučaja za C. krusei (potpun odgovor) i u 6/8 slučajeva za C. glabrata (5 potpunih, 1 djelomičan odgovor).
When Voriconazole Accord treatment is stopped by your doctor you should not experience any effects.
Kada liječnik odredi prekid liječenja lijekom Voriconazole Accord, ne biste trebali imati nikakvih nuspojava.
3 In clinical studies, response to voriconazole in C. krusei infections was similar to C. albicans, C. parapsilosis and C. tropicalis.
3 U kliničkim ispitivanjima je odgovor na vorikonazol u infekcijama čiji je uzročnik bila C. krusei bio podjednak kao u infekcijama uzročnika C. albicans, C. parapsilosis i C. tropicalis.
Digoxin (0.25 mg QD)
Digoksin (0,25 mg QD)
Some medicines, when taken at the same time as Voriconazole Accord, may affect the way Voriconazole Accord works or Voriconazole Accord may affect the way they work.
Kada se primjenjuju istodobno s lijekom Voriconazole Accord, neki lijekovi mogu utjecati na djelovanje lijeka Voriconazole Accord, ali i Voriconazole Accord može utjecati na djelovanje drugih lijekova.
However, a trend towards a higher frequency of liver enzyme elevations, reported as adverse events in clinical trials was observed in paediatric patients as compared to adults (14.2% transaminases increased in paediatrics compared to 5.3% in adults).
Međutim, u odnosu na odrasle bolesnike, kod pedijatrijskih je bolesnika u kliničkim ispitivanjima, kao nuspojava, zabilježen trend povećanja učestalosti povišenog enzima jetre (14,2% povećanih tranzaminaza u pedijatrijskih bolesnika u odnosu na 5,3% kod odraslih). odaci nakon stavljanja lijeka u promet upućuju na to da je u pedijatrijskoj populaciji moguća veća učestalost kožnih reakcija (poglavito eritema) u odnosu na odrasle.
[increases gastric pH]
[povisuje želučani pH]
Squamous cell carcinoma of the skin (SCC) has been reported in relation with long-term Voriconazole Accord treatment.
Karcinom skvamoznih stanica kože (SCC) prijavljen je u vezi s dugotrajnim liječenjem lijekom Voriconazole Accord.
inflammation of the skin, hives, sunburn or severe skin reaction following exposure to light or sun, skin redness and irritation, red or purple discoloration of the skin which may be caused by low platelet count, eczema - Infusion site reaction - Allergic reaction or exaggerated immune response
opekline od sunca ili tešku kožnu reakciju uslijed izlaganja svjetlosti ili suncu, crvenilo i nadraženost kože, crvenu ili ljubičastu promjenu boje kože koja može biti prouzročena niskim brojem trombocita, ekcem - reakcija na mjestu infuzije - alergijska reakcija ili pretjerani imunološki odgovor
EU/1/13/835/001 2 film-coated tablets EU/1/13/835/002 10 film-coated tablets EU/1/13/835/003 14 film-coated tablets EU/1/13/835/004 20 film-coated tablets EU/1/13/835/005 28 film-coated tablets EU/1/13/835/006 30 film-coated tablets EU/1/13/835/007 50 film-coated tablets EU/1/13/835/008 56 film-coated tablets EU/1/13/835/009 100 film-coated tablets EU/1/13/835/019 10x1 film-coated tablets EU/1/13/835/020 14x1 film-coated tablets EU/1/13/835/021 28x1 film-coated tablets EU/1/13/835/022 30x1 film-coated tablets EU/1/13/835/023 56x1 film-coated tablets EU/1/13/835/024 100x1 film-coated tablets
EU/1/13/835/001 2 filmom obložene tablete EU/1/13/835/002 10 filmom obloženih tableta EU/1/13/835/003 14 filmom obloženih tableta EU/1/13/835/004 20 filmom obloženih tableta EU/1/13/835/005 28 filmom obloženih tableta EU/1/13/835/006 30 filmom obloženih tableta EU/1/13/835/007 50 filmom obloženih tableta EU/1/13/835/008 56 filmom obloženih tableta EU/1/13/835/009 100 filmom obloženih tableta EU/1/13/835/019 10x1 filmom obložena tableta EU/1/13/835/020 14x1 filmom obložena tableta EU/1/13/835/021 28x1 filmom obložena tableta EU/1/13/835/022 30x1 filmom obložena tableta EU/1/13/835/023 56x1 filmom obložena tableta EU/1/13/835/024 100x1 filmom obložena tableta
Patients have developed severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) (uncommon), toxic epidermal necrolysis (TEN) (rare), drug reaction with eosinophilia and systemic symptoms (DRESS) (rare) and erythema multiforme (rare) during treatment with voriconazole (see section 4.4).
Bolesnici su tijekom primjene vorikonazola razvijali teške kožne nuspojave (engl. severe cutaneous adverse reactions, SCAR), uključujući Stevens-Johnsonov sindrom (SJS) (manje često), toksičnu epidermalnu nekrolizu (TEN) (rijetko), reakciju na lijek s eozinofilijom i sistemskim simptomima (engl. drug reaction with eosinophilia and systemic symptoms, DRESS) (rijetko) i multiformni eritem (rijetko) (vidjeti dio 4.4).
Sulfonylureas (e.g., tolbutamide, glipizide, glyburide)
Sulfonilureja (npr. tolbutamid, glipizid, gliburid)
You may experience abnormal intolerance to light as a result of taking more Voriconazole Accord than you should.
Možete osjetiti neuobičajeno nepodnošenje svjetlosti kao posljedicu uzimanja prevelike količine lijeka Voriconazole Accord.
What Voriconazole Accord contains
Što Voriconazole Accord sadrži
Other proton pump inhibitors that are CYP2C19 substrates may also be inhibited by voriconazole and may result in increased plasma concentrations of these medicinal products.
Vorikonazol može inhibirati i druge inhibitore protonske pumpe koji su supstrati CYP2C19, što može dovesti do povećanja koncentracije tih lijekova u plazmi.
Transcriptase Inhibitors (NNRTIs) (e.g., delavirdine, nevirapine)*
Ostali nenukleozidni inhibitori reverzne transkriptaze (NNRTI) (npr. delavirdin, nevirapin)*
Each tablet contains 251 mg lactose (as monohydrate).
Pomoćna tvar s poznatim učinkom Jedna tableta sadrži 251 mg laktoze (u obliku hidrata).
Oral bioavailability may be limited in paediatric patients aged 2-<12 years with malabsorption and very low body weight for age.
Bioraspoloživost nakon peroralne primjene može biti ograničena u djece u dobi od 2 do < 12 godina s malapsorpcijom ili premalom tjelesnom težinom za dob.
Coadministration of voriconazole and low dose ritonavir (100 mg BID) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.
Istodobnu primjenu vorikonazola i niske doze ritonavira (100 mg BID) treba izbjegavati, osim kad procjena odnosa koristi i rizika za bolesnika opravdava primjenu vorikonazola.
Ergot alkaloids (e.g., ergotamine and dihydroergotamine)
Ergot alkaloidi (npr. ergotamin i dihidroergotamin)
• Health Care Professional (HCP) Checklist for Phototoxicity, SCC and Hepatic toxicity: Reminds HCPs of the risks of phototoxicity, skin SCC and hepatotoxicity reported with voriconazole use.
• Kontrolni popis za zdravstvenog radnika za fototoksičnost, SCC i toksičnost za jetru: - Podsjeća zdravstvene radnike na rizik od fototoksičnosti, SCC-a kože i toksičnosti za jetru povezanih uz primjenu vorikonazola.
If a patient develops skeletal pain and radiologic findings compatible with periostitis Voriconazole Accord discontinuation should be considered after multidisciplinary advice.
Ako se u bolesnika razvije bol u skeletu, a radiološki nalazi upućuju na periostitis, nakon multidisciplinarnog savjetovanja treba razmotriti prekid primjene lijeka Voriconazole Accord.
Voriconazole Accord is intended for patients with worsening, possibly life-threatening, fungal infections.
Voriconazole Accord je namijenjen bolesnicima s gljivičnim infekcijama koje se pogoršavaju, a mogu biti opasne po život.
Voriconazole administration induced no impairment of male or female fertility in rats at exposures similar to those obtained in humans at therapeutic doses.
Primjena vorikonazola nije proizvela poremećaje plodnosti mužjaka i ženki štakora pri izloženosti sličnoj onoj koja se postiže u ljudi primjenom terapijskih doza.
Digoxin Cmax ↔ Digoxin AUCτ ↔
Digoksin Cmax ↔ Digoksin AUC ↔
Dose reduction of vinca alkaloids should be considered.
Treba razmotriti smanjenje doze vinka alakloida.
Itraconazo le (N=143)
Itrakonazol (N=143)
While being treated with Voriconazole Accord:
Za vrijeme liječenja lijekom Voriconazole Accord:
When voriconazole is coadministered with efavirenz the dose of voriconazole should be increased to 400 mg every 12 hours and the dose of efavirenz should be decreased to 300 mg every 24 hours (see sections 4.2, 4.3 and 4.5).
Kada se vorikonazol primjenjuje istodobno s efavirenzom, dozu vorikonazola treba povećati na 400 mg svakih 12 sati, a dozu efavirenza smanjiti na 300 mg svaka 24 sata (vidjeti dijelove 4.2, 4.3 i 4.5).
Mycophenolic acid (1 g single dose)
Mikofenolna kiselina (jedna doza od 1 g)
• Efavirenz (used for treating HIV) in doses of 400 mg and above once daily
• efavirenz (koristi se za liječenje HIV-a) u dozi od 400 mg i više jednom na dan
Oxycodone Cmax  1.7-fold Oxycodone AUC0-∞  3.6-fold
Oksikodon Cmax  1,7-puta Oksikodon AUC0-  3,6-puta
Voriconazole Accord, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:
Voriconazole Accord je antimikotik širokog spektra iz skupine triazola i namjenjen je za primjenu u odraslih i djece u dobi od 2 ili više godina u sljedećim indikacijama: Liječenje invazivne aspergiloze.
In an oral multiple-dose study, AUCτ was similar in subjects with moderate hepatic cirrhosis (ChildPugh B) given a maintenance dose of 100 mg twice daily and subjects with normal hepatic function given 200 mg twice daily.
U ispitivanju primjene višekratnih peroralnih doza AUCτ je bio podjednak u ispitanika s umjerenom cirozom jetre (Child-Pughov stadij B) koji su dobivali dozu održavanja od 100 mg dvaput na dan i u ispitanika s normalnom jetrenom funkcijom koji su primali dozu od 200 mg dvaput na dan.
N=241
Itrakonazol N=241
If you stop taking Voriconazole Accord
Ako prestanete uzimati Voriconazole Accord
Itraconazo le (N=109)
Itrakonazol (N=109)
Therapy must be initiated with the specified loading dose regimen of either intravenous or oral voriconazole to achieve plasma concentrations on Day 1 that are close to steady state.
Liječenje mora započeti primjenom odgovarajuće udarne doze intravenskog ili peroralnog oblika vorikonazola, kako bi se već prvog dana dosegle koncentracije lijeka u plazmi približne onima u stanju dinamičke ravnoteže.
Cardiac disorders arrhythmia supraventricular, tachycardia, bradycardia ventricular fibrillation, ventricular extrasystoles, ventricular tachycardia, electrocardiogram QT prolonged, supraventricular tachycardia torsades de pointes, atrioventricular block complete, bundle branch block, nodal rhythm
Srčani poremećaji supraventrikularna aritmija, tahikardija, bradikardija ventrikularna fibrilacija, ventrikularne ekstrasistole, ventrikularna tahikardija, produljenje QTintervala na EKGu, supraventrikularna tahikardija torsades de pointes, kompletna atrioventrikular na blokada, blokada provodnog sustava srca, nodalni ritam
Voriconazo le (N=125)
Vorikonazol (N=125)
Children (2 to <12 years) and young adolescents with low body weight (12 to 14 years and <50 kg)
Djeca (2 do < 12 godina) i mlađi adolescenti male tjelesne težine (12 do 14 godina i < 50 kg)
Frequent monitoring for opiate-associated adverse reactions may be necessary (see section 4.5).
Možda će biti potrebne česte kontrole zbog mogućih nuspojava povezanih s opijatima (vidjeti dio 4.5).
When voriconazole treatment is stopped, the initial dose of efavirenz should be restored (see section 4.2 and 4.4).
Kad se prekine liječenje vorikonazolom, treba se vratiti na početnu dozu efavirenza (vidjeti dio 4.2 i 4.4).
Coadministration of voriconazole and low dose ritonavir (100 mg twice daily) should be avoided unless an assessment of the benefit/risk to the patient justifies the use of voriconazole (see sections 4.3 and 4.5).
Treba izbjegavati istodobnu primjenu vorikonazola i niske doze ritonavira (100 mg dvaput na dan) osim ako se procijeni da omjer koristi i rizika za bolesnika opravdava primjenu vorikonazola (vidjeti dijelove 4.3 i 4.5).
Frequent monitoring for opiate associated adverse reactions may be necessary.
Možda će biti potrebne česte kontrole zbog mogućih nuspojava povezanih s opijatima.
Voriconazole Cmax  57% Voriconazole AUCτ  79% Fluconazole Cmax ND Fluconazole AUCτ ND
Vorikonazol Cmax  57% Vorikonazol AUC  79% Flukonazol Cmax ND Flukonazol AUC ND
Omeprazole Cmax 116% Omeprazole AUCτ  280% Voriconazole Cmax 15% Voriconazole AUCτ  41%
Omeprazol Cmax  116% Omeprazol AUC  280% Vorikonazol Cmax  15% Vorikonazol AUC  41%
If you forget to take Voriconazole Accord
Ako ste zaboravili uzeti Voriconazole Accord
AUCτ, AUCt and AUC0-∞represent area under the curve over a dosing interval, from time zero to the time with detectable measurement and from time zero to infinity, respectively.
AUC označava područje ispod krivulje koncentracija: vrijeme tijekom intervala doziranja, AUCt područje ispod krivulje od početne, nulte točke do vremena kad se izmjerila prva koncentracija lijeka, a AUC0- područje ispod krivulje od početne, nulte točke do beskonačnosti.
Fluconazole (200 mg QD)
Flukonazol (200 mg QD)
Voriconazole was investigated as secondary prophylaxis in an open-label, non-comparative, multicenter study of adult allogeneic HSCT recipients with prior proven or probable IFI.
Vorikonazol je ispitan kao sekundarna profilaksa u otvorenom, neusporednom, multicentričnom ispitivanju u odraslih primatelja alogene HSCT s prethodnom dokazanom ili vjerojatnom invazivnom gljivičnom infekcijom.
Each tablet contains 63 mg lactose (as monohydrate).
Pomoćna tvar s poznatim učinkom Jedna tableta sadrži 63 mg laktoze (u obliku hidrata).
If patient is unable to tolerate treatment at a higher dose, reduce the oral dose by 50 mg steps to the 200 mg twice daily (or 100 mg twice daily for patients less than 40 kg) maintenance dose.
Ako bolesnik ne podnosi liječenje tom povišenom dozom, treba smanjivati peroralnu dozu u koracima od 50 mg do doze održavanja od 200 mg dvaput na dan (odnosno 100 mg dvaput na dan u bolesnika tjelesne težine manje od 40 kg).
Scedosporium spp
Vrsta iz roda Scedosporium
IFI to day 180
Preživljenje do 180. dana
Coadministration with St John's Wort (see section 4.5).
Istodobna primjena s gospinom travom (vidjeti dio 4.5).
Phenytoin (CYP2C9 substrate and potent CYP450 inducer)
Fenitoin (supstrat CYP2C9 i snažan induktor CYP450)